IRIDEX (IRIX) Competitors

Cytosorbents (NASDAQ:CTSO) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Is CTSO or IRIX more profitable?

IRIDEX has a net margin of -22.79% compared to Cytosorbents' net margin of -49.47%. Cytosorbents' return on equity of -118.54% beat IRIDEX's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-49.47%	-118.54%	-42.31%
IRIDEX	-22.79%	-192.95%	-33.97%

Does the MarketBeat Community prefer CTSO or IRIX?

Cytosorbents received 169 more outperform votes than IRIDEX when rated by MarketBeat users. Likewise, 73.26% of users gave Cytosorbents an outperform vote while only 62.53% of users gave IRIDEX an outperform vote.

Company	Underperform	Outperform
Cytosorbents	Outperform Votes 441 73.26%	Underperform Votes 161 26.74%
IRIDEX	Outperform Votes 272 62.53%	Underperform Votes 163 37.47%

Do analysts prefer CTSO or IRIX?

Cytosorbents currently has a consensus price target of $4.67, indicating a potential upside of 362.05%. IRIDEX has a consensus price target of $2.00, indicating a potential upside of 68.07%. Given Cytosorbents' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytosorbents is more favorable than IRIDEX.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
IRIDEX	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has stronger valuation & earnings, CTSO or IRIX?

IRIDEX has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than IRIDEX, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$35.59M	1.77	-$28.51M	-$0.38	-2.66
IRIDEX	$48.67M	0.41	-$9.57M	-$0.54	-2.20

Does the media refer more to CTSO or IRIX?

In the previous week, IRIDEX had 7 more articles in the media than Cytosorbents. MarketBeat recorded 10 mentions for IRIDEX and 3 mentions for Cytosorbents. IRIDEX's average media sentiment score of 0.98 beat Cytosorbents' score of 0.47 indicating that IRIDEX is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IRIDEX	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, CTSO or IRIX?

Cytosorbents has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Do insiders and institutionals have more ownership in CTSO or IRIX?

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 20.1% of IRIDEX shares are held by institutional investors. 6.6% of Cytosorbents shares are held by insiders. Comparatively, 7.3% of IRIDEX shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cytosorbents beats IRIDEX on 11 of the 19 factors compared between the two stocks.